Form 4: Immuneering Corp: Chief Medical Officer Igor Matushansky Reports Stock Option Grant

Igor Matushansky, Chief Medical Officer of Immuneering Corp, reports the acquisition of stock options.

Summary

• On March 21, 2025, Igor Matushansky, the Chief Medical Officer of Immuneering Corporation, was granted stock options for 118,000 shares of Class A Common Stock.
• The exercise price of the options is $1.8.
• The options vest as to 25% of the underlying shares on March 17, 2026, and then in equal monthly installments over the subsequent three years, contingent upon continued employment.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a stock option grant. However, such grants are generally viewed positively as they align management incentives with shareholder value.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Risks

• The vesting of the options is contingent upon continued employment, which introduces the risk of forfeiture if the reporting person leaves the company before full vesting.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies often use similar vesting schedules, such as 25% vesting after one year followed by monthly vesting over the subsequent three years.
• The size of the grant is likely determined by the role of the executive and the overall compensation strategy of Immuneering Corp.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's success.
• The Chief Medical Officer benefits from the potential future value of the stock options.

Key Dates

Keywords

stock options, Form 4, Immuneering Corp, IMRX, Matushansky, Chief Medical Officer, beneficial ownership, equity securities